Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 125Carboplatin 123Pemetrexed 102Cisplatin 77Paclitaxel 59osimertinib 52Nivolumab 52Docetaxel 52durvalumab 46Specimen Handling 40Gemcitabine 36Magnetic Resonance Spectroscopy 35Radiosurgery 27atezolizumab 25Cetuximab 25130-nm albumin-bound paclitaxel 25Ipilimumab 22Drug Therapy 21cemiplimab 20Radiotherapy 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Biopsy 12lazertinib 11Radiation 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × camrelizumab × 90 days × Clear all
NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Guangdong Association of Clinical Trials

Phase 3 Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡